File:PMC3730064 kjo-27-235-g004.png

English⧼Colon⧽ F4: Slit-lamp photographs of the cornea of patient 12, who failed to show regression of corneal neovascularization (NV) after ranibizumab injection but demonstrated measurable regression after bevacizumab injection. The associated graph and photographs show changes in the area of corneal neovascularization (% values) after each treatment. Pre-ranibizumab injection (A): before ranibizumab injection ([A] shows the slit-lamp image obtained at that time). Postoperative day (POD) 1 week: one week after ranibizumab injection. POD 1 month (B): one month after ranibizumab injection ([B] shows the slit-lamp image obtained at that time). Pre-bevacizumab injection (C): before bevacizumab injection, thus three months after the prior ranibizumab injection ([C] shows the aggravation of corneal NV in the slit-lamp image obtained at that time). POD 1 week: one week after bevacizumab injection. POD 1 month (D): one month after bevacizumab injection ([D] shows the remarkable regression of corneal NV in the slit-lamp image obtained at that time). (E) The graph shows changes in the area of corneal neovascularization (% values) after each treatment.